- Home
- CHPT vs ADVB Comparison
CHPT vs ADVB Comparison
Compare CHPT & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHPT | ADVB |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | 31 |
| Industry | Industrial Specialties | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.1M | 109.2M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | CHPT | ADVB |
|---|---|---|
| Price | $4.69 | $4.18 |
| Analyst Decision | Hold | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $10.70 | N/A |
| AVG Volume (30 Days) | ★ 398.1K | 90.9K |
| Earning Date | 03-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.54 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $417,083,000.00 | N/A |
| Revenue This Year | $5.62 | N/A |
| Revenue Next Year | $12.92 | N/A |
| P/E Ratio | ★ N/A | $1.26 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.51 | $0.19 |
| 52 Week High | $12.62 | $5.82 |
Technical Indicators
Market Signals| Indicator | CHPT | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 28.22 | 57.26 |
| Support Level | $0.62 | $0.36 |
| Resistance Level | $6.73 | $5.71 |
| Average True Range (ATR) | 0.25 | 0.28 |
| MACD | -0.04 | -0.22 |
| Stochastic Oscillator | 0.50 | 26.82 |
Price Performance
Historical ComparisonAbout CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.
About ADVB Advanced Biomed Inc.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.